Enfortumab vedotin is another class of immunotherapy FDA approved for bladder cancer, an antibody-drug conjugate, consisting of antibodies targeting Nectin-4 conjugated with the cytotoxic agent monomethyl auristatin E (MMAE) [80]. The gene discussed is NECTIN4; the disease is urinary bladder carcinoma.